Host: Jacob Sands, MD Guest: Derek Raghavan, MD, PhD, FACP, FRACP CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Lavine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Project Oncology®

Serving the Underserved: A Look at the Role of CT Scans in Lung Cancer Screening

Host: Matt Birnholz, MD Guest: Jacob Sands, MD ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.

Uncovering the Unmet Needs of Relapsing Small Cell Lung Cancer & a Look at Platinum Rechallenge Therapy

Guest: David R. Gandara, MD Dr. David R. Gandara walks us through some of the most recent clinical trial data on non-small cell lung cancer from the 2021 American Society of Clinical Oncology Annual Meeting.

A Look at Emerging Research on Non-Small Cell Lung Cancer from ASCO 2021

Guest: Rami Manochakian, MD Dr. Rami Manochakian, a thoracic medical oncologist at the Mayo Clinic, dives into three clinical trials on developments in lung cancer treatment that were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Anticipated Advancements in Lung Cancer Treatment: A Look at the Latest Clinical Trial Data from ASCO 2021

Host: Jacob Sands, MD ReachMD host Dr. Jacob Sands joins us to share key updates that were presented on lung cancer at the American Society of ClinicalOncology Annual Meeting.

Exploring the Future of Targeted Therapies: A Look at Clinical Trial Data on Lung Cancer Treatment from ASCO 2021

Guest: Fred R. Hirsch, MD, PhD Dr. Fred R. Hirsch, Executive Director at the Center for Thoracic Oncology in the Tisch Cancer Institute at Mount Sinai and Associate Director of Biomarker Discovery for TCI discusses key studies presented at the 2021 American Society of Clinical Oncology meeting surrounding updates in lung cancer research. 

Emerging Developments in Immunotherapy & Targeted Therapies: Key Data on Lung Cancer Highlighted at ASCO 2021

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Lincoln Nadauld, MD, PhD Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.

Advancements in Cancer Screening Technology: Multicancer Early Detection

Host: Paul Paik, MD Guest: Joshua K. Sabari, MD For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC. 

Meeting Future Global Challenges: Case-Based Presentations in the Management of NSCLC

Host: Jacob Sands, MD Guest: Millie Das, MD What are some of the latest advancements in small cell lung cancer? Dr. Jacob Sands discusses small-cell lung cancer treatment developments with Dr. Millie Das, a Clinical Associate Professor of Medical Oncology at Stanford University and Chief of Oncology at the Veteran’s Affairs Palo Alto Healthcare System.

Exploring Advances in Treatment: A Step Forward in Small Cell Lung Cancer

Guest: Osita Onugha, MD, MBA Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California, is here to share multidisciplinary strategies for the treatment of non-small cell lung cancer.

Exploring Multidisciplinary Perspectives on the Treatment of Advanced Lung Cancer

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Christine Bestvina, MD Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss strategies to implement molecular diagnostics into clinical practice.

NSCLC & Optimizing Molecular Diagnostic Testing : An Exploration of Barriers to Implementation

Guest: Osita Onugha, MD, MBA Dr. Osita Onugha, thoracic surgeon at the Providence Specialty Medical Group in Santa Monica, California discusses how prognostic markers can be used to help guide non-small cell lung cancer treatment decisions.

Utilizing Prognostic Markers to Help Guide NSCLC Treatment Decisions

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Nicolas Girard, MD Dr. Charles Turck explores first-line treatment for metastatic EGFR mutated non-small cell lung cancer with pneumonologist Dr. Nicolas Girard, the head of medical oncology at the Institut Curie in Paris.

Exploring First-Line Treatment Strategies for Metastatic EGFR-Mutated NSCLC

Guest: Kelly Hunt, Md Here to give us a brief overview of her session at the 2021 American Society of Clinical Oncology Annual Meeting titled, “From Desmoid and Phyllodes to UPS: A One-Size-Does-Not-Fit-All Approach to Surgery,” is Dr. Kelly Hunt, Professor and Chair of the Department of Breast Surgical Oncology in the Division of Surgery at the University of Texas MD Anderson Cancer Center.

Lessons from ASCO: A Look at Surgery for Early Breast Cancer

Project Oncology® presents a wide array of oncology topics designed to educate and enlighten practitioners on late-breaking discoveries, novel treatment options, evolving methods of patient management, and more. This series provides cutting-edge updates on cancer biology, diagnosis, and multidisciplinary management, as well as evidence-based recommendations to achieve optimal patient outcomes.

hubhopper

Project Oncology®

hubhopper